Department of Surgery and Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Front Cell Infect Microbiol. 2023 May 16;13:1197349. doi: 10.3389/fcimb.2023.1197349. eCollection 2023.
We examined the neutralizing antibody production efficiency of the second and third severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine doses (2- and 3-dose) and neutralizing activity on mutant strains, including, the Ancestral, Beta and Omicron strains using green fluorescent protein-carrying recombinant SARS-CoV-2, in living-donor liver transplantation (LDLT) recipients.
The patients who were administered vaccines other than Pfizer- BioNTechBNT162b2 and who had coronavirus disease 2019 in this study period were excluded. We enrolled 154 LDLT recipients and 50 healthy controls.
The median time were 21 days (between 1 and 2 vaccination) and 244 days (between 2 and 3 vaccination). The median neutralizing antibody titer after 2-dose was lower in LDLT recipients than in controls (0.46 vs 1.00, P<0.0001). All controls had SARS-CoV-2 neutralizing antibodies, whereas 39 LDLT recipients (25.3%) had no neutralizing antibodies after 2-dose; age at vaccination, presence of ascites, multiple immunosuppressive treatments, and mycophenolate mofetil treatment were significant risk factors for nonresponder. The neutralizing activities of recipient sera were approximately 3-fold and 5-fold lower than those of control sera against the Ancestral and Beta strains, respectively. The median antibody titer after 3-dose was not significantly different between recipients and controls (1.02 vs 1.22, p=0.0758); only 5% recipients was non-responder. The neutralizing activity after third dose to Omicron strains were enhanced and had no significant difference between two groups.
Only the 2nd-dose was not sufficiently effective in recipients; however, 3rd-dose had sufficient neutralizing activity against the mutant strain and was as effective as that in healthy controls.
我们研究了第二剂和第三剂严重急性呼吸系统综合征冠状病毒 2（SARS-CoV-2）疫苗（2 剂和 3 剂）在活体肝移植（LDLT）受者中针对包括原始株、β株和奥密克戎株在内的突变株产生中和抗体的效率和中和活性。
本研究排除了接种非辉瑞-生物科技 BNT162b2 疫苗且在此研究期间患有 2019 年冠状病毒病的患者。我们共纳入 154 名 LDLT 受者和 50 名健康对照者。
第 2 剂和第 3 剂之间的中位时间分别为 21 天（1 剂和 2 剂之间）和 244 天（2 剂和 3 剂之间）。2 剂后，LDLT 受者的中和抗体滴度中位数低于对照组（0.46 对 1.00，P<0.0001）。所有对照者均有 SARS-CoV-2 中和抗体，而 2 剂后 39 名 LDLT 受者（25.3%）无中和抗体；接种年龄、腹水、多种免疫抑制治疗和吗替麦考酚酯治疗是无应答的显著危险因素。受者血清的中和活性分别比对照者血清对原始株和β株低约 3 倍和 5 倍。3 剂后，受者和对照组的抗体滴度中位数无显著差异（1.02 对 1.22，p=0.0758）；仅 5%的受者为无应答者。对奥密克戎株的第 3 剂后的中和活性增强，两组间无显著差异。
只有第 2 剂对受者效果不佳；然而，第 3 剂对突变株具有足够的中和活性，与健康对照者的效果相当。
